Waverly Advisors LLC acquired a new position in Haleon plc (NYSE:HLN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 31,281 shares of the company's stock, valued at approximately $298,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in shares of Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock worth $19,758,000 after purchasing an additional 475,934 shares during the last quarter. Atria Wealth Solutions Inc. raised its stake in shares of Haleon by 6.1% in the fourth quarter. Atria Wealth Solutions Inc. now owns 47,868 shares of the company's stock worth $457,000 after purchasing an additional 2,758 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Haleon by 13.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 850,563 shares of the company's stock worth $8,114,000 after purchasing an additional 99,666 shares during the last quarter. Savant Capital LLC raised its stake in shares of Haleon by 99.2% in the fourth quarter. Savant Capital LLC now owns 26,393 shares of the company's stock worth $252,000 after purchasing an additional 13,142 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Haleon by 6.1% in the fourth quarter. American Century Companies Inc. now owns 719,890 shares of the company's stock worth $6,868,000 after purchasing an additional 41,189 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.
Haleon Stock Performance
Shares of HLN traded down $0.02 on Friday, reaching $11.32. 13,223,039 shares of the company's stock traded hands, compared to its average volume of 8,423,821. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a market cap of $50.99 billion, a PE ratio of 33.28, a PEG ratio of 2.82 and a beta of 0.24. The stock's 50 day simple moving average is $10.38 and its two-hundred day simple moving average is $9.95. Haleon plc has a 52-week low of $8.25 and a 52-week high of $11.40.
Haleon (NYSE:HLN - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. On average, analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target for the company in a research report on Friday, May 9th. Wall Street Zen downgraded Haleon from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target for the company in a research report on Tuesday. Six investment analysts have rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $12.33.
Read Our Latest Report on HLN
About Haleon
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Further Reading
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
